Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study

Leukemia Research

Volumn 35, Issue 9, 2011, Pages 1184-1187

  Sánchez Guijo, Fermin M ^a   Durán, Soledad ^b   Galende, Josefina ^c   Boqué, Concepción ^d   Nieto, José B ^e   Balanzat, Josep ^f   Gracia, Antonio ^g   García, Isabel ^h   Avellaneda Molina, Carmen ⁱ   Moreno, María Victoria ^j   Luño Fernandez, Elisa ^k   Hermosilla, Mar ^l   Sanchez Varela, José Manuel ^m   Dios, Ana ⁿ   López Garrido, Pilar ^o   Giraldo, Pilar ^p   Bargay, Joan ^q   Domingo, José María ^r   Soler, Alfonso ^s   Salinas, Ramón ^t   Del Cañizo, Maria Consuelo ^a   more..

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b Hosp Univ Ciudad de Jaén   (Spain)

^c HOSPITAL EL BIERZO   (Spain)

^d CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^e HOSPITAL MORALES MESEGUER   (Spain)

^f HOSPITAL CAN MISSES   (Spain)

^g HOSPITAL TORRECÁRDENAS   (Spain)

^h HOSPITAL INFANTA MARGARITA   (Spain)

ⁱ HOSPITAL SAN AGUSTÍN   (Spain)

^j HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^k HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^l HOSPITAL JOSEP TRUETA   (Spain)

^m Universidad de La Coruña   (Spain)

ⁿ HOSPITAL MONTECELO   (Spain)

^o HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^p HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^q HOSPITAL SON LLÀTZER   (Spain)

^r HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^s Hospital Universitari Parc Taulí   (Spain)

^t Althaia   (Spain)

more..

Author keywords

Chronic myeloid leukemia; Elderly; Imatinib

Indexed keywords

HYDROXYUREA; IMATINIB; INTERFERON;

ABDOMINAL PAIN; AGE; AGED; ANEMIA; ANOREXIA; ANXIETY; ARTHRALGIA; ARTICLE; ASTHENIA; BIOCHEMISTRY; BLEEDING; BLOOD ANALYSIS; CARDIOVASCULAR DISEASE; CHRONIC MYELOID LEUKEMIA; COMORBIDITY; CONSTIPATION; CYTOGENETICS; DEMOGRAPHY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EDEMA; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; INFECTION; LARYNX PAIN; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; NAUSEA AND VOMITING; NEUTROPENIA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RASH; RIGOR; SIDE EFFECT; SORE THROAT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; WEIGHT REDUCTION; XEROSTOMIA;

EID: 80051469954     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.01.017     Document Type: Article

References (13)

1. Valent P. Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor?. Eur J Clin Invest 2010, 40:918-931.
2. Rohrbacher M., Hasford J. Epidemiology of chronic myeloid leukaemia (CML). Best Pract Res Clin Haematol 2009, 22:295-302.
3. Baccarani M., Cortes J., Pane F., Niederwieser D., Saglio G., Apperley J., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27:6041-6051.
4. Baccarani M., Saglio G., Goldman J., Hochhaus A., Simonsson B., Appelbaum F., et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006, 108:1809-1820.
5. Hasford J., Pfirrmann M., Hehlmann R., Allan N.C., Baccarani M., Kluin-Nelemans J.C., et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998, 90:850-858.
6. Sokal J.E., Cox E.B., Baccarani M., Tura S., Gomez G.A., Robertson J.E., et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984, 63:789-799.
7. Cortes J., Talpaz M., O'Brien S., Giles F., Beth R.M., Shan J., et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 2003, 98:1105-1113.
8. Latagliata R., Breccia M., Carmosino I., Sarlo C., Montefusco E., Mancini M., et al. Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment. Leuk Res 2005, 29:287-291.
9. Rosti G., Iacobucci I., Bassi S., Castagnetti F., Amabile M., Cilloni D., et al. Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. Haematologica 2007, 92:101-105.
10. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
11. Bender B.S. Infectious disease risk in the elderly. Immunol Allergy Clin North Am 2003, 23:57-64. vi.
12. Irminger-Finger I. Science of cancer and aging. J Clin Oncol 2007, 25:1844-1851.
13. Driver J.A., Djousse L., Logroscino G., Gaziano J.M., Kurth T. Incidence of cardiovascular disease and cancer in advanced age: prospective cohort study. BMJ 2008, 337:a2467.